Tonix Pharmaceuticals Holding is a clinical-stage biopharmaceutical company that specializes in developing innovative therapies and vaccines for a wide range of medical conditions. With a focus on central nervous system disorders, immunology conditions, infectious diseases, and rare diseases, Tonix is dedicated to improving patient outcomes and alleviating suffering. Tonix's portfolio includes a diverse range of products and candidates that target various therapeutic areas.

In the central nervous system field, they are developing TNX-102 SL, a promising candidate for the management of fibromyalgia and Long COVID. For immunology conditions, Tonix is working on TNX-1500, an anti-CD40L monoclonal antibody, and TNX-1700, which aims to address gastric and colorectal cancers. In the infectious disease area, their lead candidate is TNX-801, a live virus vaccine for smallpox and monkeypox.

Lastly, Tonix is developing TNX-2900 for the treatment of Prader-Willi syndrome, a rare genetic cause of childhood obesity. As a publicly traded company listed on the NASDAQ exchange, Tonix Pharmaceuticals Holding is committed to advancing medical science and delivering effective solutions to patients in need